Annovis Bio Inc. (ANVS)
1.91
-0.08 (4.02%)
Upcoming Events
Latest Headlines
Annovis Bio regains NYSE listing compliance
May 26, 2026 8:01 AM - StreetInsider
Annovis Bio Regains NYSE Listing Compliance
May 26, 2026 8:00 AM - StreetInsider
Form 4 Annovis Bio, Inc. For: May 20 Filed by: Hoffman Michael B
May 21, 2026 8:11 PM - SEC Filing
Form 8-K Annovis Bio, Inc. For: May 20
May 20, 2026 4:16 PM - SEC Filing
Form 424B5 Annovis Bio, Inc.
May 20, 2026 4:12 PM - SEC Filing
Annovis Bio prices $15 million public offering at $1.90 per share
May 20, 2026 8:01 AM - StreetInsider
Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants
May 20, 2026 8:00 AM - Globe NewsWire
Form 424B5 Annovis Bio, Inc.
May 19, 2026 5:26 PM - SEC Filing
Annovis Bio launches public offering of stock and warrants
May 19, 2026 4:06 PM - StreetInsider
Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants
May 19, 2026 4:06 PM - Globe NewsWire
Form 10-Q Annovis Bio, Inc. For: Mar 31
May 15, 2026 4:35 PM - SEC Filing
Form 8-K Annovis Bio, Inc. For: May 15
May 15, 2026 4:02 PM - SEC Filing
Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results
May 15, 2026 7:30 AM - Globe NewsWire
Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026
May 7, 2026 7:35 AM - StreetInsider
Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026
May 7, 2026 7:30 AM - Globe NewsWire
Form DEFA14A Annovis Bio, Inc.
April 30, 2026 5:05 PM - SEC Filing
Form DEF 14A Annovis Bio, Inc. For: Jun 17
April 30, 2026 4:55 PM - SEC Filing
Annovis Bio publishes Alzheimer's trial results in Nature journal
April 28, 2026 8:01 AM - StreetInsider
Annovis publishes alzheimer's drug trial results in Nature journal
April 28, 2026 8:01 AM - StreetInsider
Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio
April 28, 2026 8:01 AM - Globe NewsWire
Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio
April 28, 2026 8:01 AM - StreetInsider
Annovis Bio raises $10 million to fund alzheimer's drug development
April 10, 2026 8:39 AM - StreetInsider
Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission
April 10, 2026 8:39 AM - StreetInsider
Annovis raises $10 million to fund alzheimer's drug through phase 3 trial
April 10, 2026 8:31 AM - StreetInsider
Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission
April 10, 2026 8:30 AM - Globe NewsWire
Form 8-K Annovis Bio, Inc. For: Apr 09
April 10, 2026 6:02 AM - SEC Filing
Form 424B5 Annovis Bio, Inc.
April 9, 2026 5:10 PM - SEC Filing
Annovis Bio prices $10 million stock offering with warrants
April 9, 2026 8:31 AM - StreetInsider
Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants
April 9, 2026 8:30 AM - StreetInsider
The Credibility Filter Wall Street Uses to Sort Biotech Winners
April 8, 2026 9:15 AM - StreetInsider
Form 4 Annovis Bio, Inc. For: Apr 02 Filed by: Hoffman Michael B
April 3, 2026 5:06 PM - SEC Filing
Form 144 Annovis Bio, Inc. Filed by: White Mark K.
April 2, 2026 4:39 PM - SEC Filing
Annovis Bio gets US patent for buntanetap treating brain infection injuries
April 2, 2026 7:30 AM - StreetInsider
Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections
April 2, 2026 7:30 AM - StreetInsider
Annovis Publishes Historical Review of Buntanetap in The Scientist
March 31, 2026 8:00 AM - StreetInsider
Form 8-K Annovis Bio, Inc. For: Mar 23
March 25, 2026 5:19 PM - SEC Filing
Annovis partners with NeuroRPM for AI biomarker platform in PD study
March 19, 2026 7:31 AM - StreetInsider
Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study
March 19, 2026 7:30 AM - Globe NewsWire
NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial
March 19, 2026 7:30 AM - Globe NewsWire
Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study
March 19, 2026 7:30 AM - StreetInsider
NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial
March 19, 2026 7:30 AM - StreetInsider
Form 8-K Annovis Bio, Inc. For: Mar 16
March 16, 2026 5:06 PM - SEC Filing
Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results
March 16, 2026 7:30 AM - StreetInsider
Form 10-K Annovis Bio, Inc. For: Dec 31
March 13, 2026 5:16 PM - SEC Filing
Full Article List
